Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other endocrine-driven cancers. The news flow around OLMA reflects its active clinical development program, capital markets activity, and ongoing corporate updates.
Investors and followers of Olema’s news can expect frequent updates on its lead product candidate, palazestrant (OP-1250), an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) being evaluated in ER+/HER2- metastatic breast cancer. Company announcements include progress in pivotal Phase 3 trials such as OPERA-01 and OPERA-02, data presentations from Phase 1b/2 studies of palazestrant in combination with ribociclib, and details on additional Phase 1/2 combination studies with agents like palbociclib, alpelisib, everolimus, and atirmociclib.
Olema’s news stream also covers pipeline developments for OP-3136, a KAT6 inhibitor in Phase 1 clinical evaluation as monotherapy and in combination with fulvestrant and palazestrant in advanced solid tumors. Regulatory and collaboration milestones, such as clinical trial agreements with Pfizer to study palazestrant plus atirmociclib, are disclosed through press releases and SEC filings.
In addition, Olema regularly reports financial and operating results, underwritten public offerings of common stock under its shelf registration on Form S-3, and inducement grants of stock options to new employees under its 2022 Inducement Plan. The company also announces participation in healthcare and investor conferences, where it presents updates on its clinical programs and strategy. Readers who follow OLMA news gain insight into trial progress, collaboration agreements, financing activities, and other corporate events that shape Olema’s development as a clinical-stage oncology company.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 24,000 shares, effective February 2, 2026. The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $25.65.
The awards were approved by the Compensation Committee and issued under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA) announced that Shane Kovacs, Chief Operating and Financial Officer, is departing effective January 30, 2026 to pursue new opportunities and will remain as a consultant through August 1, 2026. The company has begun an immediate search for a successor, and President and CEO Sean P. Bohen, M.D., Ph.D., has assumed the role of interim Principal Financial Officer.
The release notes Kovacs helped advance palazestrant to late-stage clinical development, build a finance team, and establish a strong capital position.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to 8 new employees to purchase an aggregate of 223,500 shares, effective January 2, 2026.
The awards were approved under Olema's 2022 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). Options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $25.28 per share — equal to the last reported Nasdaq sale price on January 2, 2026. Awards are subject to plan terms and continuous employment for vesting.
Olema Oncology (Nasdaq: OLMA) announced that Sean P. Bohen, M.D., Ph.D., President and CEO will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2025 at 11:15 a.m. PT (2:15 p.m. ET).
A live webcast and any accompanying presentation materials will be accessible in the Events and Presentations section of Olema's investor relations website at ir.olema.com, and a recording will be posted after the event.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 65,000 shares, effective December 1, 2025. The awards were approved by the Compensation Committee under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $27.95 per share, equal to the last reported Nasdaq sale price on December 1, 2025. The grants are subject to the Inducement Plan terms.
Olema Oncology (Nasdaq: OLMA) will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET. The company is a clinical-stage biopharmaceutical focused on targeted therapies for breast cancer and related indications.
Live webcasts and recordings will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
Olema Oncology (Nasdaq: OLMA) closed an underwritten public offering of 11,500,000 common shares, including the full exercise of the underwriters' option to purchase 1,500,000 additional shares, at $19.00 per share.
Gross proceeds to Olema, before underwriting discounts, commissions and estimated offering expenses, were approximately $218.5 million. The offering relied on a shelf registration on Form S-3 declared effective January 15, 2025 and a related Form S-3MEF filed and automatically effective on November 18, 2025. Book-running managers included TD Cowen, Evercore ISI, Guggenheim Securities, LifeSci Capital, Oppenheimer, and H.C. Wainwright.
Olema Oncology (Nasdaq: OLMA) priced an underwritten public offering of 10,000,000 common shares at $19.00 per share, for gross proceeds of approximately $190.0 million. The company granted underwriters a 30-day option to buy up to an additional 1,500,000 shares at the public offering price, less discounts and commissions. The offering is expected to close on November 20, 2025, subject to customary closing conditions.
Book-running managers include TD Cowen, Evercore ISI, Guggenheim Securities, LifeSci Capital, Oppenheimer & Co., and H.C. Wainwright & Co. The offering is made under a shelf registration (Form S-3) declared effective January 15, 2025; final prospectus supplements will be filed with the SEC.
Olema Oncology (Nasdaq: OLMA) announced a proposed public offering of common stock and, for some investors, pre-funded warrants, subject to market and other conditions.
The offering is to be made from a shelf registration on Form S-3 declared effective January 15, 2025. Olema expects to grant underwriters a 30-day option to buy up to an additional 15% of the total shares and shares underlying the pre-funded warrants. TD Cowen is acting as book-running manager. No assurance exists regarding timing, size, or terms; a preliminary prospectus supplement will be filed with the SEC and made available on SEC.gov.
Olema Oncology (NASDAQ: OLMA) reported third-quarter 2025 results and clinical progress on Nov 10, 2025. Key developments include a clinical trial collaboration with Pfizer to evaluate palazestrant plus atirmociclib, initiation of the OPERA-02 Phase 3 trial of palazestrant with ribociclib in frontline ER+/HER2- metastatic breast cancer, and presented updated Phase 1b/2 palazestrant+ribociclib data at ESMO 2025.
Financials: $329.0M in cash, cash equivalents, and marketable securities as of Sept 30, 2025; GAAP net loss of $42.2M for Q3 2025 versus $34.6M year-ago. GAAP R&D was $40.0M for the quarter. Company expects OPERA-01 topline in H2 2026 and to initiate the palazestrant+atirmociclib study in Q4 2025.
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
